Actual state of ex vivo chemoresistance testing of malignant tumors in Masaryk Memorial Cancer Institute Brno;Současný stav testování chemorezistence nádorů ex vivo v Masarykově onkologickém ústavu v Brně

Klinicka Onkologie

Volumn 21, Issue 3, 2008, Pages 116-121

  Poprach, A ^a   Michalova E ^a   Pavlik T ^b   Lakomy R ^a   Vyskocil J ^a   Nemecek R ^a   Zaloudik J ^a   Vyzula, R ^a   Kocak I ^a   Kocakova I ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Chemoresistance; Cytostatics agents; Malignant melanoma; Mtt test; Ovarian carcinoma; Renal carcinoma; Soft tissue sarcoma

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; INTERLEUKIN 2; LOMUSTINE; MESNA; PACLITAXEL; PREDNISONE; TOPOTECAN; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER CELL; CANCER CENTER; CANCER STAGING; CARDIOTOXICITY; CHEMOSENSITIVITY; EX VIVO STUDY; GASTROINTESTINAL SYMPTOM; HUMAN; IN VIVO STUDY; KIDNEY CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; OVARY CANCER; RECURRENT CANCER; REPRODUCIBILITY; SOFT TISSUE SARCOMA; SOLID TUMOR; DRUG RESISTANCE; DRUG SCREENING; FEMALE; KIDNEY TUMOR; OVARY TUMOR; SARCOMA;

DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; KIDNEY NEOPLASMS; MELANOMA; OVARIAN NEOPLASMS; SARCOMA;

EID: 46449084904     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Michalová E., Poprach A., Němečková I. et al. Predikce citlivosti nádorovych buněk k chemoterapeutikům ex vivo - úskalí a limitace vlastní metody. Klinická onkologie, 2008, v tisku.
2. Klener P. et al. Etiologie a patogeneze nádorového procesu. In: Klener P. et al. (eds). Klinická onkologie, 1.vydání Praha, Galén, 2002, s. 62-65.
3. Baker F.L., Sanger L.J., Rodgers R.W. et al. Cell proliferation kinetics of normal and tumor tissue in vitro: quiescent reproductive cells and the cycling reproductive fraction. Cell Prolif, 1995; 28 (1), s. 1-15.
4. Talač R., Žaloudík J., Hajdúch M. et al. Hodnocení lékové rezistence in vitro a její klinické implikace. Klinická ontologie, 2000,13 (Speciál), s. 2-3.
5. Keiholz U., Goey S.H., Punt C.J. et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncology, 1997, 15 (7), s. 2578-2579.
6. Balch C.A.M., Atkins M.B., Sober A.J. Cutaneous Melanoma. In: DeVita V.T., Jr., Hellman S., Rosenberg S.A.(eds). Cancer, Principles and Practise of Oncology, 7th edition, Philadelphia, Lippincott Wiliams & Wilkins, 2005, s. 1798-1803.
7. Benjamin R.S., Legha S.S., Patel S.R. et al. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol, 1993, 31 (Suppl 2), s. 174-179.
8. Tierney J.F., Mosseri V., Stewart L.A. et al. Adjuvant chemotherapy for soft-tissue sarcoma: rewiev and meta-analysis of the published results of radnomised clinical trials. Br J Cancer, 1995, 72 (2),s. 469-475.
9. Brennan M.F., Singer S., Maki R.G. Sarcomas of the Soft Tissues and bones. In: DeVita V.T., Jr., Hellman S., Rosenberg S.A.(eds). Cancer, Principles and Practise of Oncology. 7th edition, Philadelphia, Lippincott Wiliams & Wilkins, 2005, s. 1624-1631.
10. Thigpen J.T., Blessing J.A., Beecham J. et al. Phase II trial of cisplatin as first- line chemotherapy in patients with advanced or recurrent uterine sarcomas. J Clin Oncol, 1991, 9 (11), s. 1962-1966.
11. Yagoda A., Abi- Rached B., Petrylak D. Chemotherapy for advanced renal carcinoma: 1983-1993. Semin Oncol, 1995, 22 (1), s. 42-60.
12. Motzer R.J., Russo P., Systemic therapy for renal carcinoma. J Urol, 2000, 163 (2), s. 408-417.
13. Atzopdien J., Kirchner H., Hanninen E. et al. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell carcinoma. Eur J Cancer, 1993, 29A (Suppl 5), s. S6-S8.
14. Tourani J.M., Pfister C., Tubiana N. et al. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design - the Subcutaneous Administration Propeukin Program Cooperative Group.. J Clin Oncol, 2003, 21 (21), s. 3987-3994.
15. Muss H.B. Interferon therapy for renal cell carcinoma. Semin Oncol , 1987, 14 (2 Suppl 2), s. 36-42.
16. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. N Engl J Med, 2007, 365 (2), s. 115-124.
17. Escudier B., Eisen T., Stadler W.M. et al. Sorafenib in Advanced Clear - Cell Renall - Cell Carcinoma. N Engl J Med, 2007, 356 (2), s. 125-134
18. Dušek L., Mužík J., Kubásek M. et al. Český národní webový portál epidemiologie nádorů [online]. Masarykova univerzita, [2005], [cit. 2008-2-25]. Dostupný z WWW: http://www.svod.cz. Verze 7.0 [2007], ISSN 1802-8861
19. Cwiertka K., Hajdúch M., Pilka R. et al. Chemoterapie ovariálního karcinomu s ohledem na stanovení in vitro chemosenzitivity - vybrané kazuistiky. Klinická Onkologie, 2000, 13 (Speciál 2), s. 58-59.
20. Stuart G., Bertelsen K., Mangioni C. et al. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: Mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish intergroup trial. Proc Am Soc Clin Oncol, 1998, 17, s. 361a.
21. Piccart M.J., Bertelsen K., Stuart G. et al. Is cisplatin-paclitaxel the standard in first-line treatment of advanced ovarian cancer? The EORTC-GCCG, NOCOVA, NCI-C and Scottish intergroup experience. Proc Am Soc Clin Oncol, 1997, 16, s. 352.
22. Ozols R.F., Bundy B.N., Fowler J. et al. Randomized phase III study of cisplatin/paclitaxel versus carboplatin/paclitaxel in optimal stage III epithelial ovarian cancer: a Gynecologic Oncology Group trial. Proc Am Soc Clin Oncol, 1999, 18, s. 365a.
23. Karlan B.Y., Markman M., Eifel P.J. Ovarian Cancer, Peritoneal Carcinoma and Fallopian Tube Carcinoma. In: DeVita V.T., Jr., Hellman S., Rosenberg S.A. (eds). Cancer, Principles and Practise of Oncology, 7th edition, Philadelphia, Lippincott Wiliams & Wilkins, 2005, s.1364-1388.
24. Klener P. et al. Nádory Vaječníků a vejcovodů. In: Klener P. et al. (eds). Klinická onkologie, 1.vydání Praha, Galén, 2002, s. 481-488.
25. Kalábová, R., Čechovský, P. Maligní nádory vaječníků. In Adam Z. et al. Diagnostické a léčebné postupy u maligních chorob. Praha: Grada Publishing, 2002, s. 213-221.
26. Krásná L., Matoušková E., Janoušek M. et al. Využití buněk získaných z maligních výpotků k vedení léčby pacientů s pokročilým nádorem. Klinická onkologie, 2000, 13 (Speciál 2), s. 43-48.